Aurigene NP-12 is primarily investigated for its potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. It functions as a glycogen synthase kinase-3 (GSK-3) inhibitor, targeting the underlying mechanisms that contribute to the progression of such conditions. By modulating GSK-3 activity, it may help reduce the formation of neurofibrillary tangles and amyloid-beta plaques, which are hallmark features of Alzheimer's. This makes it a promising candidate for slowing disease progression and improving cognitive function in patients. Additionally, its application is being explored in other conditions where GSK-3 dysregulation plays a role, such as diabetes and certain cancers. Research is ongoing to further validate its efficacy and safety in clinical settings.